On October 9, 2020, Everest Medicines Limited (“Everest” or “the Company”, 1952.HK) successfully listed on the Hong Kong Stock Exchange (“HKEx”). The pre-green shoe offering size is around US$ 451 million, and the post-green shoe offering size is around US$ 519 million. The offering was sought after by a large number of investors, and the HKPO received a 654-time oversubscription. CICC acted as the Joint Global Coordinator, Joint Book Runner and Joint Lead Manager of this offering.

Everest is a biopharmaceutical company that integrates licensing, clinical development and commercialization of potentially globally first-in-class or best-in-class therapies to address critical unmet medical needs in Greater China and other emerging Asia Pacific markets. Since the founding of the Company in 2017, Everest has created a highly scalable platform, assembled an experienced and visionary management team, and has built a portfolio of eight promising clinical-stage drug candidates across oncology, immunology, cardio-renal disease, and infectious disease. Everest believes their insight-driven, highly productive business development engine, exceptional clinical development and regulatory teams and integrated commercial platform position it to accelerate developmental timelines for innovative drug candidates and to benefit from China’s new regulatory and reimbursement policies.

Against the background of NCP and the unstable environment of the global market, CICC contributed to the successful launch of the project with proactive market promotions. The total Hong Kong Offer Shares subscription received represented approximately 654 times of the total number of Hong Kong Offer Shares initially available for subscription under the HKPO. The deal attracted strong participation from long-only funds and healthcare-dedicated funds. The successful completion of the transaction marks a promising start for the long-term cooperation between CICC and Everest, laying a solid foundation for the future cooperation between the two parties.

CICC's efficient execution capabilities in this project were highly recognized by the issuer. As a leading investment bank with “Chinese Roots, International Reach”, CICC will continue to utilize its capital market expertise as well as its seamless cooperation of onshore and offshore businesses to provide continuous support to our customers in terms of introduction of global investors, reaching international capital market, and promoting global business development.